Aurobindo Pharma Limited has informed the Exchange regarding a press release dated March 15, 2024, titled "Press Release that is being issued by the Company in connection with announcement by CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the Company, the successful Phase 1 clinical study outcome of their BP11 product (a biosimilar to Xolair).".